Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.59 |
| ▸ | PTGFR | P43088 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258715 | 0.87 | FFAR1 (0.48) | FFAR1FFAR4LMNAGLACNR1 | |
| SCHEMBL2772477 | 0.87 | FFAR1 (0.53) | FFAR1FFAR4LMNAGLACNR1 | |
| SCHEMBL1560262 | 0.86 | FFAR1 (0.53) | FFAR1FFAR4 | |
| SCHEMBL24968899 | 0.85 | FFAR1 (0.46) | FFAR1FFAR4LMNAGLACNR1 | |
| SCHEMBL3491515 | 0.85 | FFAR1 (0.72) | FFAR1FFAR4PTGFRLMNACNR1 | |
| SCHEMBL4840290 | 0.82 | FFAR1 (0.60) | FFAR1FFAR4PTGFRLMNACNR1 | |
| SCHEMBL1247027 | 0.82 | FFAR1 (0.44) | FFAR1FFAR4LMNAGLACNR1 | |
| SCHEMBL1559856 | 0.80 | FFAR1 (0.47) | FFAR1FFAR4 | |
| SCHEMBL21885801 | 0.79 | FFAR1 (0.61) | FFAR1FFAR4PTGFRLMNAGSK3B | |
| SCHEMBL3584403 | 0.78 | KEAP1 (0.63) | FFAR1FFAR4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-8017602-B2 | N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2303873-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009154557-A1 | BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105642-A1 | NOVEL COMPOUNDS 409 | GPR119, CYP4B1, CYP4A11 | FFAR1 909/4885FFAR4 612/4885PTGFR 1020/4885 |
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | FFAR1 934/4885FFAR4 1411/4885PTGFR 668/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | FFAR1 934/4885FFAR4 1411/4885PTGFR 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.